Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment

Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment

Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, r...

Full description

Bibliographic Details
Main Authors:	M. V. Shestakova, M. B. Antsiferov, A. S. Ametov, G. R. Galstyan, T. Y. Demidova, A. M. Mkrtumyan, N. A. Petunina
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2021-07-01
Series:	Сахарный диабет
Subjects:	diabetes mellitus alogliptin pioglitazone fixed combination
Online Access:	https://www.dia-endojournals.ru/jour/article/view/12757

Similar Items

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
by: Hae Jin Kim, et al.
Published: (2022-09-01)

Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin
by: N. A. Petunina, et al.
Published: (2019-01-01)

Alogliptin: efficiency, safety, new possibilities
by: L. Yu. Morgunov
Published: (2020-05-01)

MODERN POSSIBILITIES OF THERAPY OF TYPE 2 DIABETES MELLITUS PATIENTS. EFFECTIVENESS AND CARDIOSAFETY OF ALOGLIPTIN FROM THE POINT OF VIEW OF EVIDENCE-BASED MEDICINE
by: A. S. Ametov, et al.
Published: (2017-07-01)

CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN
by: N. A. Petunina, et al.
Published: (2017-12-01)

Long-term results of transferring the patient from therapy with glucagon-like peptide-1 receptor agonists in combination with metformin to a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone and inhibitor of type 2 sodium-glucose cotransporter in type 2 diabetes
by: V. V. Salukhov, et al.
Published: (2024-03-01)

Alogliptin – the new member of DPP-4 inhibitors class
by: Nina Aleksandrovna Petunina, et al.
Published: (2014-12-01)

Cardiovascular safety in the treatment of diabetes mellitus type 2: focus on alogliptin
by: A. L. Terekhova, et al.
Published: (2016-12-01)

PREDICTION OF ANTI-DIABETIC ALOGLIPTIN STABILITY BY ISOTHERMAL STUDIES
by: Charise Dallazem Bertol, et al.
Published: (2023-10-01)

Earth-friendly micellar UPLC technique for determination of four hypoglycemic drugs in different pharmaceutical dosage forms and spiked human plasma
by: Manal S. Elmasry, et al.
Published: (2023-07-01)

Salting-out induced liquid–liquid microextraction for alogliptin benzoate determination in human plasma by HPLC/UV
by: Sherin F. Hammad, et al.
Published: (2021-01-01)

Formulation and Optimization of Alogliptin-Loaded Polymeric Nanoparticles: In Vitro to In Vivo Assessment
by: Dibyalochan Mohanty, et al.
Published: (2022-07-01)

Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial
by: João Pedro Ferreira, et al.
Published: (2020-06-01)

Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring
by: Arumugam Kodimuthali, et al.
Published: (2010-07-01)

Utility of picric acid and 2,4 dinitrophenol as chromogenic reagents for visible spectrophotometric quantification of alogliptin
by: A.V.V.N.K. Sunil Kumar, et al.
Published: (2017-06-01)

A developed HPLC method for the determination of Alogliptin Benzoate and its potential impurities in bulk drug and tablets
by: Kun Zhang, et al.
Published: (2015-04-01)

Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis
by: Chin-Hsiao Tseng
Published: (2022-05-01)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
by: Xu Liu, et al.
Published: (2021-09-01)

Investigation of Alogliptin-Loaded In Situ Gel Implants by 2<sup>3</sup> Factorial Design with Glycemic Assessment in Rats
by: Tarek M. Ibrahim, et al.
Published: (2022-09-01)

Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case–control study
by: Min-Hee Woo, et al.
Published: (2019-05-01)

Enantioselective Box Behenken Optimized HPLC-DAD Method for the Simultaneous Estimation of Alogliptin Enantiomorphs in Pharmaceutical For mulations and their Pharmacokinetic Study in Rat Plasma
by: Ravi Kant, et al.
Published: (2019-02-01)

Combination of Pioglitazone and Metformin Actions on Liver Lipid Metabolism in Obese Mice
by: Jieying Liu, et al.
Published: (2023-07-01)

Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus
by: Chin-Hsiao Tseng
Published: (2022-12-01)

Corrigendum: Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
by: Jingxuan Lian, et al.
Published: (2022-02-01)

Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report
by: Noda Yoko, et al.
Published: (2013-01-01)

The association between pioglitazone consumption and incidence of bladder cancer in type II diabetic patients: a systematic review and meta-analysis of observational studies
by: Pantea Ramezannezhad, et al.
Published: (2023-03-01)

Pioglitazone: A boon we know less about
by: Dilip Gude
Published: (2013-01-01)

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice
by: Dongmei Wang, et al.
Published: (2022-10-01)

Determination of Pioglitazone Hydrochloride in Tablets by High-Performance Liquid Chromatography
by: AMR Lotfy Saber
Published: (2008-12-01)

SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01)

The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
by: Sun Ok Song, et al.
Published: (2012-10-01)

Pioglitazone: Indian perspective
by: Rishi Shukla, et al.
Published: (2011-01-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial
by: Mondal Aashish, et al.
Published: (2024-02-01)

The Safety and Efficacy of Combining Saxagliptin and Pioglitazone Therapy in Streptozocin-Induced Diabetic Rats
by: Ahmed Mohamed Othman, et al.
Published: (2023-12-01)

A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population
by: V Balaji, et al.
Published: (2014-01-01)

Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study
by: Sunil Gupta, et al.
Published: (2015-01-01)

Liquid Chromatographic Determination of Pioglitazone in Pharmaceuticals, Serum and Urine Samples
by: Shahnaz Perveen, et al.
Published: (2011-12-01)

Comparison of efficacy of add-on therapy of vildagliptin versus pioglitazone among Type 2 Diabetes Mellitus patients inadequately controlled on dual therapy of metformin plus sulfonylurea
by: Kirandeep Kaur
Published: (2014-02-01)

Pioglitazone use and the risk of bladder cancer
by: Hsin-Wei Kuo, et al.
Published: (2014-02-01)